🚀 VC round data is live in beta, check it out!
Satellos Bioscience Valuation Multiples
Discover revenue and EBITDA valuation multiples for Satellos Bioscience and similar public comparables like Abeona Therapeutics, Journey Medical, Oryzon Genomics, Palisade Bio and more.
Satellos Bioscience Overview
About Satellos Bioscience
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.
Founded
2012
HQ
Employees
27
Website
Sectors
Financials (LTM)
EV
$231M
Satellos Bioscience Financials
Satellos Bioscience reported last 12-month revenue of — and negative EBITDA of ($24M).
In the same LTM period, Satellos Bioscience generated — in gross profit, ($24M) in EBITDA losses, and had net loss of ($27M).
Revenue (LTM)
Satellos Bioscience P&L
In the most recent fiscal year, Satellos Bioscience reported revenue of — and EBITDA of ($20M).
Satellos Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($24M) | XXX | ($20M) | XXX | XXX | XXX |
| Net Profit | ($27M) | XXX | ($20M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Satellos Bioscience Stock Performance
Satellos Bioscience has current market cap of $265M, and enterprise value of $231M.
Market Cap Evolution
Satellos Bioscience's stock price is $12.84.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $231M | $265M | -0.3% | XXX | XXX | XXX | $-0.95 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSatellos Bioscience Valuation Multiples
Satellos Bioscience trades at (9.8x) EV/EBITDA.
EV / Revenue (LTM)
Satellos Bioscience Financial Valuation Multiples
As of March 29, 2026, Satellos Bioscience has market cap of $265M and EV of $231M.
Equity research analysts estimate Satellos Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Satellos Bioscience has a P/E ratio of (9.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $265M | XXX | $265M | XXX | XXX | XXX |
| EV (current) | $231M | XXX | $231M | XXX | XXX | XXX |
| EV/EBITDA | (9.8x) | XXX | (11.8x) | XXX | XXX | XXX |
| EV/EBIT | (8.5x) | XXX | (11.9x) | XXX | XXX | XXX |
| P/E | (9.9x) | XXX | (13.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (13.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Satellos Bioscience Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Satellos Bioscience Margins & Growth Rates
Satellos Bioscience's revenue in the last fiscal year grew by —.
Satellos Bioscience's revenue per employee in the last FY averaged $0.0M.
Satellos Bioscience Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 9% | XXX | 18% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Satellos Bioscience Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Abeona Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Journey Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Oryzon Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Palisade Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Animalcare Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Satellos Bioscience M&A Activity
Satellos Bioscience acquired XXX companies to date.
Last acquisition by Satellos Bioscience was on XXXXXXXX, XXXXX. Satellos Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Satellos Bioscience
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSatellos Bioscience Investment Activity
Satellos Bioscience invested in XXX companies to date.
Satellos Bioscience made its latest investment on XXXXXXXX, XXXXX. Satellos Bioscience invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Satellos Bioscience
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Satellos Bioscience
| When was Satellos Bioscience founded? | Satellos Bioscience was founded in 2012. |
| Where is Satellos Bioscience headquartered? | Satellos Bioscience is headquartered in Canada. |
| How many employees does Satellos Bioscience have? | As of today, Satellos Bioscience has over 27 employees. |
| Is Satellos Bioscience publicly listed? | Yes, Satellos Bioscience is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Satellos Bioscience? | Satellos Bioscience trades under MSCL ticker. |
| When did Satellos Bioscience go public? | Satellos Bioscience went public in 2021. |
| Who are competitors of Satellos Bioscience? | Satellos Bioscience main competitors are Abeona Therapeutics, Journey Medical, Oryzon Genomics, Palisade Bio. |
| What is the current market cap of Satellos Bioscience? | Satellos Bioscience's current market cap is $265M. |
| Is Satellos Bioscience profitable? | No, Satellos Bioscience is not profitable. |
| What is the current EBITDA of Satellos Bioscience? | Satellos Bioscience has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Satellos Bioscience? | Current EBITDA multiple of Satellos Bioscience is (9.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.